Sugi Predict

Sugi Predict / Compounds / SCHEMBL14332678

SCHEMBL14332678

SCHEMBL14332678

O=C(O)c1ccc2c(c1)CNC2=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMYD3 Q9H7B4 1/20 0.58
▸ PRF1 P14222 1/20 0.52
▸ GRM5 P41594 2/20 0.51
▸ TDP2 O95551 3/20 0.49
▸ SRD5A2 P31213 4/20 0.49
▸ SRD5A1 P18405 3/20 0.49
▸ CA12 O43570 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GSK3B P49841 2/20 0.45
▸ CLK4 Q9HAZ1 2/20 0.45
▸ DAPK3 O43293 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ PIM1 P11309 1/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ ROCK1 Q13464 1/20 0.45
▸ TTR P02766 1/20 0.44
▸ TYRO3 Q06418 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
M-Xylene SCHEMBL1788893 0.88 CLK4 (0.51) SMYD3PRF1GRM5TDP2SRD5A2
SCHEMBL5879567 0.86 TDP2 (0.61) SMYD3PRF1GRM5TDP2SRD5A2
SCHEMBL14683952 0.84 NPC1 (0.58) SMYD3PRF1GRM5TDP2CA12
SCHEMBL29544439 0.84 PRF1 (0.66) SMYD3PRF1GRM5TDP2CA12
SCHEMBL19691136 0.84 PRF1 (0.66) SMYD3PRF1GRM5TDP2CA12
SCHEMBL1417726 0.83 PARP11 (0.58) GRM5TDP2SRD5A2SRD5A1KDM4E
SCHEMBL30337030 0.83 PARP11 (0.58) GRM5TDP2SRD5A2SRD5A1KDM4E
SCHEMBL23933229 0.82 SMYD3 (0.51) SMYD3PRF1GRM5CA12CA9
SCHEMBL24812335 0.80 SMYD3 (0.50) SMYD3PRF1GRM5CA12CA9
SCHEMBL25139737 0.80 SMYD3 (0.50) SMYD3PRF1GRM5CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304552-A1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF SEAL ROCK THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 — — CN disclosed
WO-2024201248-A1 COMPOUNDS AND METHODS FOR DEGRADING GSPT1 PIN THERAPEUTICS, INC. (KR) 2024-10-03 — — WO disclosed
EP-3606519-B1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF SEAL ROCK THERAPEUTICS INC (US) 2024-06-05 — — EP disclosed
EP-4352046-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF Hangzhou Glubio Pharmaceutical Co., Ltd. (CN) 2024-04-17 — — EP disclosed
CN-117561244-A Isoindolinone compounds and uses thereof 杭州格博生物医药有限公司 2024-02-13 — — CN disclosed
CN-110730661-B ASK1 inhibitor compounds and uses thereof 西尔洛克治疗公司 2023-06-13 — — CN disclosed
WO-2022257897-A1 ISOINDOLINONE COMPOUNDS, AND USES THEREOF HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD. (CN) 2022-12-15 — — WO disclosed
CN-113563245-A Substituted pyrrolidine compounds and application thereof in medicines 广东东阳光药业有限公司 2021-10-29 — — CN disclosed
US-20210087167-A1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF Seal Rock Therapeutics, Inc. 2021-03-25 — — US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 — — WO disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 — — US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 — — US disclosed
WO-2013067036-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-05-10 — — WO disclosed
WO-2013018735-A1 AMIDINE COMPOUND OR SALT THEREOF 大正製薬株式会社 (JP) 2013-02-07 — — WO disclosed
WO-2012177893-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2012-12-27 — — WO disclosed
WO-2012177893-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2012-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087167-A1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF ATF1, MAP3K1, ROCK1 SMYD3 1926/4885PRF1 4002/4885GRM5 4690/4885
US-20250304552-A1 ASK1 INHIBITOR COMPOUNDS AND USES THEREOF ATF1, MAP3K1, ROCK1 SMYD3 1926/4885PRF1 4002/4885GRM5 4690/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 SMYD3 4130/4885PRF1 1651/4885GRM5 393/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 SMYD3 3884/4885PRF1 1946/4885GRM5 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.